



11-19-03

1654

Attorney Docket No. 9233-8DV1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Ekwuribe et al.  
Application Serial No.: 09/429,798  
Filed: October 29, 1999  
For: *Blood-Brain Barrier Therapeutics*

Confirmation No.: 6336  
Group Art Unit: 1654

Date: November 18, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a form PTO-1449 (two pages), providing a list of documents 1-15, previously made of record in parent application serial number 09/134,803 from which the present application claims priority and/or in application serial number 09/430,735, which is a sister divisional application of the present application that also claims priority to parent application serial number 09/134,803. Because these references have already been made of record in these related applications, a copy of each of these references is not provided herein. However, applicants will provide a copy of any such reference cited herein upon request from the Examiner. Also included as item 16 is a reference not previously of record, and a copy is enclosed. Applicants respectfully request that these documents be considered and officially made of record in the present application in accordance with the provisions of C.F.R. § 1.56 and Section 609 of the MPEP.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b). Accordingly, no fee is believed due. However, the Commissioner is authorized to charge any deficiency or credit any refund to Deposit Account No. 50-0220.

Respectfully submitted,

Mary L. Miller  
Registration No. 39,303

USPTO Customer No. 20792  
Myers Bigel Sibley & Sajovec, P.A.  
Post Office Box 37428  
Raleigh, NC 27627  
Telephone (919) 854-1400  
Facsimile (919) 854-1401

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No.: EV 353610934 US  
Date of Deposit: November 18, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Cathy A. Schetzina





Substitute form 1449A/PTO				<b>Compleat if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/429,798
				Filing Date	October 29, 1999
				First Named Inventor	Ekwuribe
				Group Art Unit	1654
				Examiner Name	Brenda G. Brumback
Sheet	2	of	2	Attorney Docket Number	9233.8DV1

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	12.	Nucci et al. "The Therapeutic Value of Poly(ethylene glycol) – Modified Proteins" <i>Ac. Drug. Del. Rev.</i> 6:133-151 (1991)	
	13.	Abuchowski and Davis "Soluble Polymer-Enzyme Adducts" <i>Enzymes as Drugs</i> , Holcenberg and Wiley (1981)	
	14.	Akiyama et al. "The Synthesis of New Derivatives of 1-β-D-Arabinofuranosylcytosine" <i>Chem. Pharm. Bull.</i> 26(3):981 (1978)	
	15.	Zalipsky et al. "Attachment of Drugs to Polyethylene Glycols" <i>Eur. Polym. J.</i> 19:121177-1183 (1983)	
	16.	Anderson et al. "Structure-Activity Relationship Assessment of Conjugated Enkephalins in Centrally Mediated Analgesia" <i>Soc. Neurosci. Abstr.</i> 25(1):180 (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.